A Phase 1/2 interventional study of Lenalidomide and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-26.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing obinutuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 1 of them phase 3. obinutuzumab · Lymphoma, Follicular.
Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, this one is the 6th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 1/2, and was the 8th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →8 of the 30 studies testing obinutuzumab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–90
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Heidelberg University · Sites in Germany
Ages 18+
Emory University · Sites in United States
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 2 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 49 across the 30 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 30 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2016, is one of 7 in phase 1/2, and was the 13th registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
6 of the studies testing obinutuzumab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05045664Phase 3Heidelberg UniversityEarly Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | 2027-09-30 |
| NCT03980171Peter MacCallum Cancer Centre, AustraliaStudy of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | 2026-11 |
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT06549335Ruijin HospitalZanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL) | 2026-12-01 |
| NCT04450173University of California, DavisObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, from their registry updates:
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (R/R) follicular lymphoma (FL) and rituximab in combination with polatuzumab vedotin and lenalidomide in participants with R/R diffuse large B-cell lymphoma (DLBCL), followed by post-induction treatment with obinutuzumab in combination with lenalidomide in participants with FL who achieve a complete response (CR), partial response (PR), or stable disease (SD) at end of induction (EOI) and post-induction treatment with rituximab plus lenalidomide in participants with DLBCL who achieve a CR or PR at EOI.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
This study's enrollment of 114 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Browse Lymphoma, Follicular studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R FL will receive 6 months of induction treatment with polatuzumab vedotin and lenalidomide at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and lenalidomide when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 24-month maintenance regimen consisting of lenalidomide and obinutuzumab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
Drug: Lenalidomide · Drug: Obinutuzumab · Drug: Polatuzumab Vedotin
Participants with R/R DLBCL will receive 6 months of induction treatment with fixed dose of polatuzumab vedotin and rituximab along with dose escalating lenalidomide. Lenalidomide will be administered at escalating doses to identify the recommended Phase 2 dose (RP2D) for lenalidomide. Those who achieve CR and PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will be eligible to receive a 6-month consolidation regimen consisting of lenalidomide and rituximab, to be initiated 8 weeks after Day 1 of Cycle 6 (induction cycle).
Drug: Lenalidomide · Drug: Polatuzumab Vedotin · Drug: Rituximab
Participants with R/R FL who received induction treatment with polatuzumab vedotin and lenalidomide, in addition to obinutuzumab and achieved CR, PR, or SD at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 24-months maintenance regimen consisting of lenalidomide and obinutuzumab for first 12 months followed by obinutuzumab treatment for next 12 months. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
Drug: Lenalidomide · Drug: Obinutuzumab
Participants with R/R DLBCL who received induction treatment with polatuzumab vedotin and lenalidomide in addition to rituximab and achieved CR or PR at the EOI (6-8 weeks after Day 1 of Cycle 6) will receive a 6-month consolidation regimen consisting of lenalidomide and rituximab. Post-induction therapy will start 8 weeks after Cycle 6 Day 1.
Drug: Lenalidomide · Drug: Rituximab
All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
Percentage of Participants With Dose-Limiting Toxicities (DLTs)
A DLT was defined as any one of the following toxicities occurring during the first cycle of treatment and assessed by the investigator as related to study treatment: Any adverse event of any grade that lead to a delay of \> 14 days in the start of the next treatment cycle, Grade 3 or 4 non-hematologic adverse events with few exceptions; increase in hepatic transaminase \> 3 x baseline and an increase in direct bilirubin \> 2 x upper limits of normal (ULN), without any findings of cholestasis or jaundice, or signs of hepatic dysfunction, and in the absence of other contributory factors; hematologic adverse events that met a few protocol specified criteria. DLTs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Percentages have been rounded off to the first decimal point.
Time frame: Day 1 of Cycle 1 to Day 1 of Cycle 2 (1 cycle = 28 days) in dose-escalation phase
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Percentages have been rounded off to the first decimal point.
Time frame: From study start up to end of study (Up to a maximum of 69 months)
Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans
CR at EOI was assessed by IRC according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans
CR at EOI was assessed by Investigator according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone
CR at EOI was determined by IRC according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone
CR at EOI was determined by Investigator according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans
OR was defined as percentage of participants with CR or PR as assessed by the IRC according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake\> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. Partial response (PR) based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages have been rounded off up to the second decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (cycle=28 days) (up to approximately 28 weeks)
Percentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans
OR was defined percentage of participants with CR or PR assessed by the investigator according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, 3 with or without residual mass on 5PS, where 1=no uptake above background 2=uptake ≤ mediastinum 3=uptake\> mediastinum but ≤ liver 4=uptake moderately \> liver 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline(diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages are rounded off.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone
OR was defined as the percentage of participants with CR or PR, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone
OR was defined as the percentage of participants with CR or PR, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
Time frame: 6 to 8 weeks after Day 1 of Cycle 6 (up to approximately 28 weeks)
Percentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone
BOR=CR/PR per CT per MLRC. Per MLRC, CR based on CT was defined as a complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Percentages have been rounded off to the first decimal point.
Time frame: Up to every 6 months until disease progression, unacceptable toxicity or study completion (up to approximately 69 months)
Observed Serum Obinutuzumab Concentration
1 cycle = 28 days
Time frame: Day 1 of Cycles 1, 2, 4 & 6: predose & 30 mins postdose; EOI: predose; Day 1 of Maintenance Months 1,7, 13, 19;Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)
Observed Serum Rituximab Concentration
Time frame: Day 1 of Cycles 1, 2, 4, 6: predose and 30 mins post-dose (1 cycle = 28 days) (up to approximately 69 months)
Serum Concentration of Polatuzumab Vedotin Analyte: Total Antibody
Time frame: Day 1 of Cycles 1, 2, 4: predose (1 cycle = 28 days), Day 120 post last dose; one year post last dose; study drug discontinuation; unscheduled visit: predose (up to approximately 69 months)
Plasma Concentration of Polatuzumab Vedotin Analyte: Antibody-conjugated MMAE (acMMAE)
Time frame: Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1; Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)
Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
Time frame: Day 1 of Cycles 1, 2, 4: predose and 30 mins post-dose; Days 8 and 15 of Cycle 1 and Day 1 of Cycle 6: predose, study drug discontinuation; unscheduled visit: predose (1 cycle = 28 days) (up to approximately 69 months)
Observed Plasma Lenalidomide Concentration
Time frame: Day 1 Cycle 1: predose and 2 hours (hr) post-dose; Day 15 Cycle 1: predose, 0.5hr, 1hr, 2hr, 4hr, 8hr post-dose; Day 1 Cycle 6: 2hr post-dose; unscheduled visits: 2hr post-dose (1 cycle = 28 days) (up to approximately 69 months)
Number of Participants With Human Anti-human Antibodies (HAHAs) to Obinutuzumab
The number of participants with positive results for HAHAs, also called anti-drug antibodies (ADAs) against obinutuzumab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.
Time frame: Baseline up to approximately 2 years after last dose (up to approximately 69 months)
Number of Participants With Human Anti-chimeric Antibodies (HACAs) to Rituximab
The number of participants with positive results for HACAs, also called ADAs against rituximab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
Time frame: Baseline up to approximately 2 years after last dose (up to approximately 69 months)
Number of Participants With Anti-therapeutic Antibodies (ATAs) to Polatuzumab Vedotin
The number of participants with positive results for ATAs, also called ADAs against polatuzumab vedotin at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
Time frame: Baseline up to approx. 2 years after the last dose of polatuzumab vedotin (up to approximately 30 months)
A total of 114 participants with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) were enrolled in this study at 28 investigative sites in Spain, United Kingdom, and United States from 24 March 2016 to 15 December 2021. The study consisted of two phases: dose-escalation and dose-expansion phase. All eligible participants in both phases received induction and post-induction therapy.
| Milestone | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 40 | 40 |
| Intent-to-treat population | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 40 | 40 |
| Safety-evaluable population | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 40 | 39 |
| Immunogenicity-evaluable population | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 39 | 38 |
| Pharmacokinetic-evaluable population | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 40 | 39 |
| Completed | 1 | 2 | 2 | 4 | 0 | 3 | 0 | 28 | 17 |
| Not completed | 2 | 2 | 1 | 2 | 3 | 2 | 10 | 12 | 23 |
| Withdrew: Death | 1 | 2 | 1 | 2 | 3 | 2 | 10 | 7 | 20 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
A DLT was defined as any one of the following toxicities occurring during the first cycle of treatment and assessed by the investigator as related to study treatment: Any adverse event of any grade that lead to a delay of \> 14 days in the start of the next treatment cycle, Grade 3 or 4 non-hematologic adverse events with few exceptions; increase in hepatic transaminase \> 3 x baseline and an increase in direct bilirubin \> 2 x upper limits of normal (ULN), without any findings of cholestasis or jaundice, or signs of hepatic dysfunction, and in the absence of other contributory factors; hematologic adverse events that met a few protocol specified criteria. DLTs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Dose-Limiting Toxicities (DLTs) | 0.0 | 50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 97.4 |
CR at EOI was assessed by IRC according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Complete Response (CR) at End of Induction (EOI), Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography (CT) Scans | 66.7 (27.13 to 93.72) | 0.0 (0.0 to 25.89) | 60.0 (45.78 to 73.06) | 38.5 (25.41 to 52.89) |
CR at EOI was assessed by Investigator according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake \> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With CR at EOI, Determined by the Investigator on the Basis of PET-CT Scans | 66.7 (27.13 to 93.72) | 0.0 (0.0 to 25.89) | 60.0 (45.78 to 73.06) | 33.3 (20.97 to 47.69) |
CR at EOI was determined by IRC according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With CR at EOI, Determined by the IRC on the Basis of CT Scans Alone | 16.7 (0.85 to 58.18) | 0.0 (0.0 to 31.23) | 31.4 (18.73 to 46.61) | 12.5 (4.38 to 26.36) |
CR at EOI was determined by Investigator according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With CR at EOI, Determined by Investigator on the Basis of CT Scans Alone | 16.7 (0.85 to 58.18) | 0.0 (0.0 to 28.31) | 29.7 (17.65 to 44.38) | 28.1 (15.53 to 43.94) |
OR was defined as percentage of participants with CR or PR as assessed by the IRC according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake\> mediastinum but ≤ liver; 4=uptake moderately \> liver; 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. Partial response (PR) based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages have been rounded off up to the second decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Objective Response (OR) at EOI, Determined by the IRC on the Basis of PET-CT Scans | 100.0 (60.70 to 100.0) | 10.0 (0.51 to 39.42) | 72.50 (58.61 to 83.75) | 46.20 (32.35 to 60.42) |
OR was defined percentage of participants with CR or PR assessed by the investigator according to MLRC. Per MLRC CR based on PET-CT is complete MR in lymph nodes \& ELS with score of 1, 2, 3 with or without residual mass on 5PS, where 1=no uptake above background 2=uptake ≤ mediastinum 3=uptake\> mediastinum but ≤ liver 4=uptake moderately \> liver 5=uptake markedly higher than liver and/or new lesions;no new lesions \& no evidence of FDG-avid disease in bone marrow.Bone marrow is normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes \& ELS with score of 4 or 5 with reduced uptake compared with baseline \& residual masses of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline(diffuse uptake compatible with reactive changes from chemotherapy allowed). Percentages are rounded off.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Objective Response at EOI, Determined by Investigator on the Basis of PET-CT Scans | 100.0 (60.70 to 100.0) | 10.0 (0.51 to 39.42) | 80.0 (66.80 to 89.64) | 46.20 (32.35 to 60.42) |
OR was defined as the percentage of participants with CR or PR, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Objective Response at EOI, Determined by the IRC on the Basis of CT Scans Alone | 100.0 (60.70 to 100.0) | 12.5 (0.64 to 47.07) | 91.4 (79.31 to 97.62) | 53.1 (37.34 to 68.46) |
OR was defined as the percentage of participants with CR or PR, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in the sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Analysis was done 6-8 weeks after Cycle 6, Day 1 (cycle=28 days). Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of CT Scans Alone | 100.0 (60.70 to 100.0) | 11.1 (0.57 to 42.91) | 89.2 (76.95 to 96.22) | 59.4 (43.35 to 74.03) |
BOR=CR/PR per CT per MLRC. Per MLRC, CR based on CT was defined as a complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. Percentages have been rounded off to the first decimal point.
| percentage of participants | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Percentage of Participants With Best Response of CR or PR, Determined by the Investigator on the Basis of CT Scans Alone | 100.0 (60.70 to 100.0) | 50.0 (22.24 to 77.76) | 90.0 (78.56 to 96.51) | 79.5 (66.02 to 89.36) |
1 cycle = 28 days
| micrograms per milliliter (μg/mL) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL |
|---|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 1 Day 1 / 30 mins | 394 ± 22.1 | 358 ± 20.5 | 351 ± 15.2 | 333 ± 70.0 | 182 ± 206.7 |
| Induction Cycle 2 Day 1 / Predose | 451 ± 23.5 | 372 ± 37.0 | 386 ± 4.6 | 481 ± 23.1 | 312 ± 40.8 |
| Induction Cycle 2 Day 1 / 30 mins | 830 ± 38.3 | 749 ± 17.2 | 695 ± 14.3 | 667 ± 77.5 | 588 ± 41.4 |
| Induction Cycle 4 Day 1 / Predose | 354 ± 15.0 | 321 ± 43.6 | 344 ± 13.4 | 405 ± 24.9 | 270 ± 41.8 |
| Induction Cycle 4 Day 1 / 30 mins | 103 ± NA | 644 ± 42.8 | 653 ± 20.6 | 742 ± 27.8 | 547 ± 37.1 |
| Induction Cycle 6 Day 1 / Predose | 255 ± 36.6 | 504 ± NA | 327 ± 5.8 | 384 ± 52.2 | 255 ± 49.0 |
| Induction Cycle 6 Day 1 / 30 mins | 730 ± 15.5 | 804 ± NA | 1.18 ± NA | 751 ± 35.3 | 543 ± 36.2 |
| EOI / Predose | 108 ± 32.6 | — | — | — | — |
| Maintenance Month 1 / Predose | 231 ± 19.1 | 381 ± NA | — | 230 ± 87.4 | 176 ± 60.1 |
| Maintenance Month 7 / Predose | 128 ± NA | 212 ± NA | 229 ± NA | 125 ± 143.7 | 135 ± 64.3 |
| Maintenance Month 13 / Predose | — | 142 ± NA | 269 ± NA | 134 ± 105.3 | 150 ± 70.7 |
| Maintenance Month 19 / Predose | — | 354 ± NA | 204 ± NA | 154 ± 144.1 | 165 ± 59.5 |
| Study Drug Discontinuation | — | 46.4 ± NA | — | 17.3 ± NA | 87.5 ± 588.7 |
| Day 120 Post Last Dose | 29.1 ± NA | — | — | — | 44.5 ± 806.5 |
| 1 Year Post Last Dose | — | — | 0.377 ± NA | — | 0.340 ± 955.9 |
| Unscheduled / Predose | — | — | — | — | 561 ± NA |
| μg/mL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 1 Day 1 / 30 mins | 151 ± 42.9 | 203 ± 28.1 | 175 ± 18.7 | 174 ± 45.4 |
| Induction Cycle 2 Day 1 / Predose | 25.6 ± 78.0 | 33.3 ± 43.7 | 31.7 ± 26.2 | 26.4 ± 73.4 |
| Induction Cycle 2 Day 1 / 30 mins | 133 ± NA | 172 ± NA | 222 ± NA | 194 ± 36.4 |
| Induction Cycle 4 Day 1 / Predose | 20.4 ± NA | 74.6 ± 33.8 | 53.1 ± 43.7 | 58.3 ± 44.4 |
| Induction Cycle 4 Day 1 / 30 mins | 159 ± NA | 224 ± 5.7 | 220 ± 16.2 | 228 ± 36.6 |
| Induction Cycle 6 Day 1 / Predose | 15.3 ± NA | 79.5 ± 42.3 | 74.7 ± 22.1 | 68.9 ± 60.6 |
| Induction Cycle 6 Day 1 / 30 mins | 135 ± NA | 250 ± 7.6 | 233 ± 1.8 | 256 ± 26.4 |
| μg/mL | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 2 Day 1 / Predose | 1.47 ± 16.2 | 2.01 ± 51.1 | 0.200 ± 958.3 | 0.622 ± 152.8 | 1.57 ± 62.9 | 1.61 ± 59.8 | 1.47 ± 26.2 | 0.339 ± 391.8 | 1.35 ± 122.0 |
| Induction Cycle 4 Day 1 / Predose | 1.83 ± 51.7 | 4.45 ± 20.5 | 2.57 ± 30.5 | 2.12 ± 69.0 | 0.900 ± NA | 2.96 ± 44.4 | 3.10 ± 43.6 | 2.31 ± 48.5 | 3.42 ± 46.1 |
| Study Drug Discontinuation | 0.106 ± 209.1 | 0.170 ± NA | — | 0.0903 ± NA | 1.50 ± NA | 6.16 ± NA | 3.25 ± 49.7 | 0.175 ± NA | 0.455 ± 448.4 |
| Day 120 Post Last Dose | 0.0661 ± NA | — | — | — | — | 0.208 ± NA | 0.107 ± NA | 0.0365 ± NA | 0.0666 ± NA |
| 1 Year Post Last Dose | 0.0250 ± NA | — | 0.0250 ± NA | — | — | — | — | 0.0357 ± NA | 0.0250 ± NA |
| Unscheduled / Predose | — | — | — | — | — | — | — | — | 2.59 ± NA |
| nanograms per milliliter (ng/mL) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 1 Day 1 / 30 mins | 580 ± 41.6 | 660 ± 24.7 | 476 ± 16.0 | 432 ± 27.9 | 568 ± 27.7 | 106 ± 60902.6 | 513 ± 73.5 | 333 ± 267.2 | 522 ± 323.0 |
| Induction Cycle 1 Day 8 | 50.2 ± 7.3 | 80.0 ± 17.6 | 11.4 ± 232.2 | 27.7 ± 69.2 | 58.9 ± 44.4 | 52.0 ± 36.3 | 43.9 ± 96.4 | 11.9 ± 799.0 | 56.6 ± 90.2 |
| Induction Cycle 1 Day 15 | 17.3 ± 5.5 | 24.7 ± 13.8 | 2.50 ± 483.1 | 6.73 ± 118.8 | 22.3 ± 31.2 | 18.3 ± 48.7 | 18.6 ± 30.5 | 5.95 ± 366.1 | 16.9 ± 118.6 |
| Induction Cycle 2 Day 1 / Predose | 4.96 ± 21.3 | 6.55 ± 58.7 | 0.961 ± 477.5 | 2.50 ± 119.8 | 7.44 ± 40.2 | 5.58 ± 77.2 | 6.12 ± 18.1 | 1.88 ± 490.2 | 5.32 ± 103.6 |
| Induction Cycle 2 Day 1 / 30 mins | 555 ± 15.8 | 623 ± 18.4 | 508 ± 22.7 | 295 ± 174.6 | 537 ± 40.3 | 568 ± 14.1 | 716 ± 16.5 | 481 ± 54.3 | 451 ± 391.7 |
| Induction Cycle 4 Day 1 / Predose | 5.34 ± 73.9 | 11.5 ± NA | 8.47 ± 19.5 | 7.68 ± 60.8 | 4.19 ± NA | 8.25 ± 59.4 | 11.7 ± 74.2 | 8.99 ± 36.7 | 11.3 ± 45.2 |
| Induction Cycle 4 Day 1 / 30 mins | 32.9 ± 101980.7 | 416 ± 87.7 | 519 ± 9.3 | 531 ± 17.6 | 371 ± NA | 507 ± 42.8 | 737 ± 20.8 | 492 ± 22.3 | 645 ± 107.2 |
| Induction Cycle 6 Day 1 / Predose | 7.70 ± 26.0 | 19.9 ± NA | 9.37 ± 42.6 | 9.70 ± 53.0 | 3.06 ± NA | 11.5 ± 41.6 | 15.8 ± 45.4 | 9.82 ± 40.4 | 11.8 ± 66.0 |
| Study Drug Discontinuation | 0.180 ± NA | 0.635 ± NA | — | 0.180 ± NA | — | — | — | 1.71 ± 378.4 | — |
| Unscheduled / Predose | — | — | — | — | — | — | — | 23.1 ± 62.5 | 9.78 ± NA |
| ng/mL | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 1 Day 1 / 30 mins | 0.228 ± 7.8 | 0.160 ± 69.9 | 0.420 ± 100.6 | 0.233 ± 74.0 | 0.156 ± 62.1 | 0.167 ± 214.8 | 0.298 ± 198.7 | 0.347 ± 327.5 | 0.297 ± 111.1 |
| Induction Cycle 1 Day 8 | 1.15 ± 34.9 | 2.05 ± 49.7 | 2.40 ± 102.0 | 1.64 ± 135.5 | 1.89 ± 76.1 | 1.36 ± 29.6 | 3.65 ± 75.3 | 1.12 ± 227.0 | 2.56 ± 144.8 |
| Induction Cycle 1 Day 15 | 0.457 ± 56.3 | 0.459 ± 54.5 | 0.387 ± 6.0 | 0.435 ± 129.5 | 0.485 ± 204.0 | 0.456 ± 39.8 | 0.683 ± 63.3 | 0.294 ± 170.9 | 0.843 ± 125.2 |
| Induction Cycle 2 Day 1 / Predose | 0.0280 ± NA | 0.0315 ± NA | 0.0244 ± NA | 0.0334 ± NA | 0.0501 ± 149.0 | 0.0310 ± NA | 0.0527 ± 102.8 | 0.0268 ± NA | 0.0713 ± 125.0 |
| Induction Cycle 2 Day 1 / 30 mins | 0.151 ± 68.6 | 0.138 ± 133.0 | 0.151 ± 49.8 | 0.136 ± 339.9 | 0.186 ± 51.2 | 0.123 ± 53.8 | 0.157 ± 72.5 | 0.102 ± 101.2 | 0.210 ± 77.3 |
| Induction Cycle 4 Day 1 / Predose | 0.0431 ± NA | 0.117 ± NA | 0.0672 ± 56.9 | 0.0283 ± NA | 0.0180 ± NA | 0.0344 ± 61.0 | 0.0729 ± 11.4 | 0.0366 ± NA | 0.0776 ± 101.5 |
| Induction Cycle 4 Day 1 / 30 mins | 0.0817 ± NA | 0.156 ± 18.7 | 0.104 ± 7.1 | 0.0752 ± 113.2 | 0.0180 ± NA | 0.133 ± 50.9 | 0.208 ± 44.9 | 0.102 ± 57.7 | 0.213 ± 51.3 |
| Induction Cycle 6 Day 1 / Predose | 0.0367 ± 68.3 | 0.0929 ± NA | 0.0821 ± 93.8 | 0.0267 ± NA | 0.0180 ± NA | 0.0517 ± 118.9 | 0.0405 ± NA | 0.0342 ± NA | 0.0852 ± 62.6 |
| Study Drug Discontinuation | 0.0180 ± NA | 0.0180 ± NA | — | 0.0180 ± NA | — | — | — | 0.0180 ± NA | — |
| Unscheduled / Predose | — | — | — | — | — | — | — | 0.180 ± NA | 0.0180 ± NA |
| ng/mL | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Induction Cycle 1 Day 1 / Predose | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Induction Cycle 1 Day 1 / 2h | 118 ± 44.0 | 144 ± 30.3 | 201 ± 54.0 | 305 ± 37.1 | 25.2 ± 239.4 | 237 ± 47.4 | 197 ± 184.1 | 306 ± 43.1 | 277 ± 60.0 |
| Induction Cycle 1 Day 15 / Predose | 5.97 ± 628.0 | 0.729 ± 540.0 | 8.74 ± 277.0 | 5.20 ± 275.1 | 5.43 ± 9.1 | 2.64 ± 68.0 | 8.33 ± 112.0 | 9.99 ± 260.9 | 10.4 ± 196.4 |
| Induction Cycle 1 Day 15 / 30 min | 64.0 ± 1553.1 | 1.95 ± NA | 179 ± 220.1 | 202 ± 115.6 | 12.5 ± 76.4 | 41.7 ± 546.7 | 73.3 ± 395.5 | 124 ± 300.3 | 94.5 ± 204.9 |
| Induction Cycle 1 Day 15 / 1h | 61.4 ± 1354.8 | 40.8 ± 183.1 | 189 ± 48.0 | 272 ± 48.2 | 69.9 ± 10.3 | 224 ± 76.8 | 187 ± 150.5 | 236 ± 147.7 | 245 ± 106.8 |
| Induction Cycle 1 Day 15 / 2h | 117 ± 53.2 | 93.3 ± 40.5 | 202 ± 36.0 | 200 ± 45.5 | 118 ± 22.3 | 232 ± 25.5 | 328 ± 38.2 | 305 ± 53.6 | 242 ± 297.2 |
| Induction Cycle 1 Day 15 / 4h | 96.4 ± 62.0 | 65.7 ± 46.3 | 116 ± 28.9 | 152 ± 36.9 | 79.9 ± 28.2 | 134 ± 23.6 | 245 ± 36.3 | 214 ± 41.1 | 205 ± 45.4 |
| Induction Cycle 1 Day 15 / 8h | 35.0 ± 109.1 | 29.2 ± 55.2 | 56.8 ± 57.2 | 49.8 ± 23.3 | 44.0 ± 40.2 | 57.0 ± 19.1 | 105 ± 50.9 | 103 ± 56.3 | 103 ± 67.6 |
| Induction Cycle 6 Day 1 / 2h | 124 ± 21.4 | 76.1 ± NA | 110 ± 35.1 | 227 ± 48.1 | 36.2 ± NA | 258 ± 10.5 | 255 ± 36.5 | 237 ± 52.1 | 153 ± 515.5 |
| Unscheduled / 2h | — | — | — | — | — | — | — | 199 ± 53.3 | — |
The number of participants with positive results for HAHAs, also called anti-drug antibodies (ADAs) against obinutuzumab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result.
| Participants | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL |
|---|---|---|---|---|---|
| Baseline prevalence of ADAs | 0 | 0 | 0 | 0 | 3 |
| Post baseline incidence of ADAs | 0 | 0 | 0 | 0 | 0 |
The number of participants with positive results for HACAs, also called ADAs against rituximab at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
| Participants | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|
| Baseline prevalence of ADAs | 0 | 0 | 0 | 0 |
| Post baseline incidence of ADAs | 0 | 0 | 0 | 0 |
The number of participants with positive results for ATAs, also called ADAs against polatuzumab vedotin at baseline and at any of the post-baseline assessment time-points were reported. Number of participants positive for Treatment Emergent ADA = the number of post-baseline evaluable participants determined to have treatment induced ADA or treatment-enhanced ADA during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
| Participants | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| Baseline prevalence of ADAs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Post baseline incidence of ADAs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over From Baseline up to study completion/discontinuation (maximum of 69 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | 2/5 (40%) | 0/5 (0%) | 5/5 (100%) |
| Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 10/10 (100%) | 4/10 (40%) | 9/10 (90%) |
| Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | 7/40 (17.5%) | 26/40 (65%) | 40/40 (100%) |
| Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | 20/39 (51.3%) | 19/39 (48.7%) | 37/39 (94.9%) |
| Event | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/4 | 1/3 | 0/6 | 0/3 | 0/5 | 0/10 | 4/40 | 1/39 |
| ACUTE CORONARY SYNDROMECardiac disorders | 0/3 | 0/4 | 1/3 | 0/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| COLITISGastrointestinal disorders | 1/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| DIARRHOEAGastrointestinal disorders | 1/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| PYREXIAGeneral disorders | 1/3 | 0/4 | 0/3 | 1/6 | 0/3 | 0/5 | 0/10 | 2/40 | 2/39 |
| SEPTIC SHOCKInfections and infestations | 0/3 | 0/4 | 1/3 | 0/6 | 0/3 | 0/5 | 0/10 | 1/40 | 0/39 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 1/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| URINARY TRACT INFECTIONInfections and infestations | 0/3 | 1/4 | 0/3 | 0/6 | 0/3 | 0/5 | 0/10 | 1/40 | 0/39 |
| ANKLE FRACTUREInjury, poisoning and procedural complications | 0/3 | 1/4 | 0/3 | 0/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/4 | 0/3 | 1/6 | 0/3 | 0/5 | 0/10 | 0/40 | 0/39 |
| Event | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL |
|---|---|---|---|---|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 1/3 | 2/4 | 1/3 | 6/6 | 2/3 | 3/5 | 7/10 | 26/40 | 25/39 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/3 | 2/4 | 1/3 | 5/6 | 1/3 | 1/5 | 2/10 | 22/40 | 10/39 |
| DIARRHOEAGastrointestinal disorders | 2/3 | 2/4 | 2/3 | 1/6 | 1/3 | 1/5 | 2/10 | 17/40 | 13/39 |
| NAUSEAGastrointestinal disorders | 1/3 | 1/4 | 2/3 | 0/6 | 1/3 | 0/5 | 0/10 | 8/40 | 5/39 |
| FATIGUEGeneral disorders | 1/3 | 0/4 | 2/3 | 0/6 | 0/3 | 1/5 | 0/10 | 11/40 | 6/39 |
| PYREXIAGeneral disorders | 2/3 | 0/4 | 2/3 | 3/6 | 1/3 | 1/5 | 1/10 | 13/40 | 5/39 |
| RASHSkin and subcutaneous tissue disorders | 2/3 | 1/4 | 1/3 | 0/6 | 0/3 | 0/5 | 4/10 | 5/40 | 7/39 |
| ANAEMIABlood and lymphatic system disorders | 1/3 | 0/4 | 1/3 | 3/6 | 1/3 | 2/5 | 5/10 | 18/40 | 14/39 |
| ASTHENIAGeneral disorders | 0/3 | 2/4 | 1/3 | 1/6 | 1/3 | 0/5 | 2/10 | 7/40 | 6/39 |
| BLOOD CREATININE INCREASEDInvestigations | 0/3 | 2/4 | 0/3 | 1/6 | 0/3 | 1/5 | 0/10 | 5/40 | 3/39 |
The ITT population included all participants enrolled in the study.
| Age, Continuous(years) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 61.3 ± 6.1 | 72.5 ± 8.1 | 56.0 ± 3.5 | 58.3 ± 12.0 | 59.7 ± 6.5 | 62.0 ± 14.9 | 61.4 ± 14.2 | 61.6 ± 11.2 | 68.4 ± 12.8 | 64.0 ± 12.2 |
| Sex: Female, Male(Participants) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 4 | 0 | 1 | 4 | 12 | 14 | 42 |
| Male | 1 | 1 | 1 | 2 | 3 | 4 | 6 | 28 | 26 | 72 |
| Race (NIH/OMB)(Participants) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 4 | 3 | 6 | 3 | 5 | 10 | 36 | 38 | 108 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Dose-escalation Phase: 1.4 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 15 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Dose-escalation Phase: 1.8 mg Pola + 10 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 15 mg L + 375 mg R in DLBCL | Dose-escalation Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Expansion Phase: 1.4 mg Pola + 20 mg L + 1000 mg G in FL | Expansion Phase: 1.8 mg Pola + 20 mg L + 375 mg R in DLBCL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 12 |
| Ethnicity — Not Hispanic or Latino | 3 | 4 | 2 | 6 | 3 | 4 | 7 | 34 | 34 | 97 |
| Ethnicity — Not Stated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 4 |
| Ethnicity — Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Dec 2021, 68 months.
Results were first posted in Dec 2023, 2 years after primary completion.
Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 68 months is close to that.
Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Obinutuzumab · Polatuzumab vedotin · Rituximab